checkAd
    Startseite > Aktien > Immix Biopharma > Nachrichten
    Immix Biopharma Aktie
    2,0000
     
    USD
    -10,71 %
    -0,2400 USD
    Letzter Kurs 00:54:00 Nasdaq
    2,1300
     
    USD
    300 STK
    Geldkurs 09.05.24
    2,1900
     
    USD
    100 STK
    Briefkurs 09.05.24
    ISIN: US45258H1068 · WKN: A3C9EJ · SYM: IMMX · USA

    Neueste Nachrichten

    Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
    29.04.24 · globenewswire · Immix Biopharma
    Immix Biopharma on Track to Dose NXC-201 Patients in United States
    18.04.24 · globenewswire · Immix Biopharma
    Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
    15.04.24 · globenewswire · Immix Biopharma
    Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
    20.03.24 · globenewswire · Immix Biopharma
    Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
    05.03.24 · globenewswire · Immix Biopharma
    Immix Biopharma 12 Month Review Progress Update
    21.02.24 · globenewswire · Immix Biopharma
    Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
    08.02.24 · globenewswire · Immix Biopharma
    Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
    07.02.24 · globenewswire · Immix Biopharma
    Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
    06.02.24 · globenewswire · Immix Biopharma
    Immix Biopharma Announces Proposed Public Offering of Common Stock
    05.02.24 · globenewswire · Immix Biopharma
    Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
    24.01.24 · globenewswire · Immix Biopharma
    Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
    04.01.24 · globenewswire · Immix Biopharma